MedTrace Logo

Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia

NCT04451174 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-03

No results posted yet for this study

Summary

Steroids has shown benefits in COVID19 patients in observational studies. We hypothesized that early use of corticosteroids, low dose, in mild disease, can decrease progression to respiratory failure and death.

Conditions

Interventions

DRUG

Prednisone

Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Mauricio Salinas, MD · University of Chile

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2021-01-30
Completion
2021-01-30

Countries

  • Chile

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451174 on ClinicalTrials.gov